Histone deacetylases (HDAC) are a family of enzymes that have been identified as a promising target to reverse aberrant epigenetic states associated with cancer via the regulation of acetylation levels in histone.
The hydroxamic acid trichostatin A (TSA) have been known as a differentiation inducer for tumor cells, but its clinical use has been limited by high reactivity and instability. Furthermore, TSA has also been reported to be unstable in vivo following intravenous injection in mice. 4, 5) Suberoylanilide hydroxamic acid (SAHA, vorinostat, Zolinza), is a potent HDACI that has demonstrated antitumor activity in vitro against a variety of cell lines and in vivo against several human tumor xenograft models. [6] [7] [8] Furthermore, SAHA is currently prescribed to treat cutaneous T-cell lymphoma 9) and is also being tested in several phase I to III clinical trials for the treatment of a variety of other cancers, including breast, lung, and colon. 10, 11) Although SAHA is orally administrated because of its hydrophobic property, it is easily metabolized in the liver. Pharmacokinetic studies in patients after administration of SAHA have identified two inactive metabolites, SAHA-glucuronide and 4-anilino-4-oxobutanoic acid, which are pharmacologically inactive, and the mean terminal half-life (t 1/2 ) of SAHA was ca. 2.0 h 12, 13) ; therefore, the liposomal SAHA formulation warrants in vivo experiments because it allows intravenous administration and prevents metabolism in the liver.
Liposomes have the advantage of an enhanced permeability and retention effect (EPR), increasing their tumor accumulation when they are intravenously injected. 14) Such a type of nanocarrier is supposed to improve the pharmacokinetic and pharmacodistribution of the encapsulated drug. Liposomal LAQ824, hydrophilic hydroxamic acid HDACI, was shown to be both long-circulating and highly stable in vivo 14) ; however, in the encapsulation of hydrophobic SAHA into liposome, SAHA must be incorporated into the lipid membrane, which might be limited in its capacity to entrap SAHA. We therefore attempted to synthesize hydroxamatetype HDACI-lipid conjugates as a component of the liposome formulation for efficient incorporation into the liposomal membrane. Previously, we have reported that inclusion of HDACI-lipid conjugates into cationic nanopartilces as a non-viral vector could increase gene expression via hyper acetylation of histone. 15) In this study, taking into consideration the diverse derivatization, we selected SAHA and one of the K-series compounds, K-182, which has two OH groups to tether other groups with a biodegradable ester bond, and synthesized cholesteryl HDACI and HDACI-polyethylene glycol (PEG)-lipid conjugates to prepare liposomal HDACIlipid conjugates (Fig. 1) . Furthermore, we evaluated their cytotoxic effect on tumor cells via the acetylation of histone H3 and apoptotic activity.
Experimental
Synthesis of HDACI-Lipid Conjugates IR spectra were recorded on a Shimadzu FTIR-8400 infrared spectrophotometer. FAB-MS spectra were measured on a JEOL JMS-HX 100 instrument.
1 H-and 13 C-NMR spectra were recorded on JEOL EX-400 (399.7 MHz for 1 H-NMR and 100.4 MHz for 13 C-NMR) instruments using tetramethylsilane as an internal standard. Analytical and preparative TLC were performed using Silica gel 60 F254 (Merck, 0.25, 1 mm, respectively) glass plates. Column chromatography was performed using Silica Gel 60 (70-230 mesh ASTM). CM-K-182 was prepared according to the method described previously.
15)
Synthesis of Cholest-5-en-3-yl (2R)-2-{[(9H-Fluoren-9-ylmethoxy)carbonyl]amino}-3-{[(4-methoxyphenyl)(diphenyl)methyl]sulfanyl}-propanoate (2) A solution of Fmoc-Cys (Mmt) -OH (1) (500 mg, 0.81 mmol), cholesterol (314 mg, 0.81 mmol), dimethylaminopyridine (DMAP) (99 mg, 0.81 mmol) and dicyclohexylcarbodiimide (DCC) (178 mg, 0.81 mmol) in CH 2 Cl 2 (3 ml) was stirred at room temperature for 3 h (Chart 1). After the removal of DCU by filtration, the solution was diluted with CHCl 3 , washed with 0.1 M HCl, 5% NaHCO 3 and saturated NaCl and then dried over Na 2 ], 942.5125). Synthesis of 3-(2-Pyridinyldisulfanyl)propanoic Acid (7) 3-(2-Pyridinyldisulfanyl)propanoic acid (7) was synthesized according to the procedure described previously. 16 
Synthesis of Distearoylphosphatidylethanolamine (DSPE)-PEG-3-(2-pyridyldithio)propanoate (8)
To a solution of 7 (43 mg, 0.2 mmol) in CH 2 Cl 2 (1 ml) was added N-hydroxysuccineimide (HOSu, 23 mg, 0.2 mmol) and (DCC, 41 mg, 0.2 mmol) at 0°C and the mixture was stirred at room temperature for 6 h (Chart 2). After the removal of precipitates by filtration, DSPG-PEG-NH 2 (50 mg, ca. 17.4 mmol) was added to the solution and stirred for another 18 h under the same conditions. The reaction mixture was concentrated, applied to Sephadex LH-20 gel filtration column chromatography (1.5 cm i.d.ϫ45 cm) and eluted with methanol. The fractions of the eluate from 27 to 32 ml were collected and evaporated in vacuo to gave 8 (29 mg, ca. 9.4 mmol) as a colorless oil. Molecular weights of the components were calculated from electrospray ionization (ESI)-MS (ϩ) multiply charged ion peaks for 2806 (m/z 936 (Mϩ3H 
Synthesis of 2-{[(4-Methoxyphenyl)(diphenyl)methyl]sulfanyl}ethanol (10)
To a solution of 4-methoxy triphenyl methyl chloride (2.00 g, 6.4 mmol) in N,N-dimethylformamide (DMF) (12 ml) was added 2-mercaptoethanol (0.45 ml, 6.4 mmol) and triethylamine (0.90 ml, 6.4 mmol) and the solution was stirred at room temperature for 3 h (Chart 2). After the addition of CHCl 3 (30 ml), the organic layer was washed with water (30 ml) and then dried over Na 2 
Synthesis of DSPE-PEG-K-182
To a solution of 12 (30 mg, 0.039 mmol) in CH 2 Cl 2 (2.0 ml) was added CF 3 CO 2 H (16 ml) and Et 3 SiH (20 ml) and the solution was stirred at 0°C for 4 h (Chart 2). After confirmation of the complete deprotection of the p-methoxytrityl group by TLC, the solution was evaporated to remove the solvent and regents. The residual oily mixture was applied to 8 (29 mg, ca. 9.4 mml) in DMF (0.5 ml) and the solution was stirred for another 20 h at room temperature. The resulting mixture was applied to Sephadex LH-20 column chromatography (1.5 cm i.d.ϫ45 cm), eluted with methanol, and the eluate was between 20 and 26 ml, in which compounds with an average molecular weight were collected. Evaporation of the solvent gave DSPE-PEG-K-182 (25 mg, ca. 7.8 mmol) as a brownish oil. Molecular weight of the components was calculated from ESI-MS (ϩ) multiply charged ion peaks for 3192 (m/z 1065 (Mϩ3H Table 1) . As a control of liposomal HDACI-PEG-lipid conjugates, 5 mol% PEG 2000 -DSPE was added to the formulation of L (L-DSPE-PEG). The particle size distributions and the z-potentials were measured by the dynamic light scattering method and the electrophoresis light scattering method, respectively (ELS-Z2; Otsuka Electronics Co., Ltd., Osaka, Japan), at 25°C after dispersion and dilution to an appropriate volume with water.
Entrapment Efficiency of HDACI-Lipid Conjugate into Liposome Unencapsulated SAHA-lipid conjugates were removed using a Sephadex G-50 column eluted with saline adjusted to pH 7.4. After purification, the concentration of phospholipid (DSPC) in liposome suspension was measured with the Phospholipids C-test Wako (Wako Pure Chemical Industries, Ltd.). The amount of SAHA-lipid conjugate in liposomes was quantified as its acid hydrolysate, intact SAHA. Quantification of SAHA in the sample and standard mixture was performed with multiple reaction monitoring (MRM) analysis using MS/MS without chromatographic purification. To each of the standard SAHAs or SAHA-lipid conjugates in liposomal suspension (0.65 ml) was added ethanol (0.25 ml) and 12 M HCl (0.15 ml). After incubating for one hour at 50°C, the mixture was neutralized to pH 7 with 6 M NaOH at 0°C and extracted twice with ethyl acetate. The organic layer was collected, washed with brine and concentrated. The resulting extract was dissolved in methanol (0.20 ml) to afford a standard or sample solution of SAHA.
For MS/MS analysis, SAHA was analyzed by ESI-LC-MS/MS on a triplequadrupole mass spectrometer (API-3000; Applied Biosystems). The instrument was operated with a turbo ion spray interface in positive ion mode. , supplemented with 10% heat-inactivated fetal bovine serum (FBS, Invitrogen) and kanamycin (100 mg/ml) at 37°C in a 5% CO 2 humidified atmosphere.
Antiproliferative Activity The cells were seeded in 96-well plates 24 h prior to transfection. Cells at 30% confluences in the well were treated with various concentrations of HDACI-lipid conjugates or liposomal HDACIlipid conjugates for 48 h. Cell viability (%) was measured by WST-8 assay (Dojindo Laboratories, Kumamoto, Japan) as previously reported.
18)
Western Blot Analysis Western blot analysis for acetylated histone H3 and b-actin protein was performed as previously reported. 19) Briefly, Colon 26 cells were seeded in a 35-mm culture dish and incubated overnight. The cells at 30% confluency were treated with liposomal HDACI-lipid conjugates (10 mM as a concentration of HDACI-lipid) or liposomes (L or L-DSPE-PEG) and then incubated for 24 h. The cells were suspended in lysis buffer (1% Triton-X 100 in phosphate-buffered saline pH 7.4 (PBS)), and then Western blotting was performed as previously reported. 19 ) Acetylated histone H3 was identified using rabbit anti-acetyl histone H3 antibody (Sigma Chemical Co., St. Louis, MO, U.S.A.) and goat anti-rabbit immunoglobulin G (IgG) peroxidase conjugate (Santa Cruz Biotechnology, Santa Cruz, CA, U.S.A.) as the secondary antibody. The blots of b-actin protein were probed with a mouse anti b-actin IgG peroxidase conjugate (b-actin (C4) HRP; Santa Cruz Biotechnology).
Caspase 3/7 Activities Colon 26 cells were seeded in a 35-mm culture dish and incubated overnight. The cells at 30% confluences in the well were treated with liposomal HDACI-lipid conjugates for 24 h. To measure caspase 3/7 activity, a homogenous assay (Caspase-Glo TM 3/7 assay; Promega, Madison, WI, U.S.A.) was performed as previously reported.
Statistical Analysis Significant differences in the mean values were evaluated by Student's unpaired t-test. A p value of 0.05 or less was considered significant.
Results and Discussion
SAHA is orally administrated because of its hydrophobic property, and is easily metabolized in the liver 12, 13) ; therefore, we decided to incorporate a potent hydroxamic acid, HDACI, SAHA or K-182, 15) into the liposomal membrane to allow their intravenous administration and increase their acculturation in the tumor by the EPR effect. Liposomal HDACI formulation warrants in vivo experiment; however, the amount of hydrophobic drugs incorporated into liposomal membrane was limited. Therefore, we decided to synthesize HDACI- Table 1 lipid conjugates to increase the amount of HDACI incorporated into the liposomal membrane. Accordingly, we designed lipid conjugates of SAHA and K-182, in which their hydroxyl (OH) group is tethered to an aliphatic fatty acid or a cholesteryl group via linkers connected with biodegradable ester or disulfide carbonate bonds (Fig. 1) . The disulfide carbonate linker in a cholesteryl K-182, CCS-K-182, and a PEG 2000 -lipid conjugate of K-182, DSPE-PEG-K-182, is designed to release unmodified K-182 in the reductive cytosolic condition. 15) We synthesized these compounds using the procedures shown in Charts 1 and 2. The cholesteryl group of CM-K-182 and CM-SAHA is linked with succinic diester bonds, formed by coupling cholesteryl succinate to the original HDACIs, as described previously.
15) The PEG 2000 -lipid conjugates of SAHA, DSPE-PEG-SAHA and OL-PEG-SAHA, were furnished with a reaction between SAHA and commercially available N-hydroxysuccinimide (NHS) ester of DSPE-PEG 2000 or oleyl-PEG 2000 followed by purification with LH-20 gel filtration column chromatography.
For preparation of liposomal HDACI-lipid conjugates, the formulation of DSPC/Chol (L) or DSPC/Chol/DSPE-PEG 2000 (L-DSPE-PEG), which was often used for in vivo experiments, [20] [21] [22] Table 1) . The liposomal HDACI-PEG-lipid conjugates were about 90-130 nm with narrow size dispersions and negative z-potentials, which might be influenced by PEG coating ( Table  1) . The liposomal HDACI-Chol conjugates, L-CM-K-182 and L-CCS-K-182 were about 150-300 nm, but L-CM-SAHA was large (about 1 mm) ( Table 1) . Among liposomal HDACI-Chol conjugates, L-CCS-K-182 and L-CM-K-182 had positive charges in z-potential, which might be affected by a ternary amine of K-182. When size and z-potential measurements were conducted over a period of one month at 4°C, no physicochemical changes were observed. After gel filtration, we measured the entrapment efficiency of HDACIlipid conjugate into the liposome. Entrapment efficiency of HADCI-Chol conjugates into liposomes was almost 100%, but that of HDACI-PEG-lipid conjugates was about 60-70% (data not shown), suggesting that the lipid anchor of HDACI-lipid conjugate might affect modification of the surface of liposomes by HDAC-lipid; however, in subsequent experiments, we used unpurified liposomes for uniform lipid concentration among liposomal HDACI-lipids.
To investigate whether liposomal HDACI-lipid conjugates had antitumor effects on tumor cells, we treated HDACI-lipid conjugates or liposomal HDACI-lipid conjugates with HeLa and Colon 26 cells for 48 h (Table 2 Table 2 ). In particulars, L-OL-PEG-SAHA showed higher cytotoxicity than free SAHA for both cell lines (IC 50 of free SAHAϭ1.9, 9.5 mM for HeLa and Colon 26 cells, respectively), suggesting that hydroxamic acid of SAHA might be protected from hydrolysis in the medium by conjugation with lipid. When L and L-DSPE-PEG were treated at the same lipid concentrations with liposomal HDACI-lipid conjugates, they did not show any cytotoxic effects (data not shown). Generally, positively charged liposomes can be easily taken up by the cells via electrostatic interaction compared with negatively charged ones, however, cytotoxicties by liposomal HDACI-lipid conjugates were not affected by the physicochemical property and were dependent on structure of HDACI-lipid conjugates.
Histone H3 is one of the core histone proteins in the chromatin of eukaryotic cells. Hyperacetylation of lysine residues, i.e. lysine 9, in the N-terminal tails of histone H3 loosens the histone-DNA binding and activates gene transcription. On the other hand, deacetylation of acetylated lysine residues leads to tight histone-DNA binding, which restricts the access of transcriptional factors. Histone acetyltransferases (HATs) and HDACs play a crucial role in this reversible acetylation and deacetylation of histones regulating gene expression. Inhibition of HDACs therefore induces histone hyperacetylation and activates gene transcription. 23) SAHA selectively induces the expression of specific genes such as p21 WAF1/CIP1 cyclin-dependent kinase inhibitor to effect cell-cycle arrest, resulting in the induction of apoptosis. 24) We evaluated the acetylation of histone H3 and induction of apoptosis by liposomal HDACI-lipid conjugates (Fig. 2) . When liposomal HDACI-lipid conjugates were treated with Colon 26 cells for 24 h, L-CCS-K-182, L-DSPE-PEG-SAHA and L-OL-PEG-SAHA strongly induced the acetylation of histone H3 (Fig. 2A) . Furthermore, to examine the effect of histone hyperacetylation on the activity of apoptosis-associated enzymes, we measured caspase 3/7 activity 24 h after treatment with liposomal HDACI-lipid conjugates at 10 mM as a concentration of K-182 or SAHA (Fig. 2B) . Among the liposomal HDACI-lipid conjugates, L-OL-PEG-SAHA strongly increased caspase 3/7 activities about 3-fold higher than untreated cells. In L-CCS-K-182, the caspase 3/7 activity was not increased because CCS-K-182 concentration in the medium was under the IC 50 for Colon 26 cells (19.4 mM) . This observation indicated that L-OL-PEG-SAHA could efficiently release SAHA in the cells and inhibit HDAC in the nucleus, resulting in the hyperacetylation of histone H3.
In antitumor activity, L-CCS-K-182 had antitumor activity via acetylation of histone H3, but L-CM-K-182 and L-CM-SAHA did not, suggesting that the disulfide carbonate bond between HDACI and Chol was easily cleavable in cytoplasm, but the ester bond was not. In contrast, L-DSPE-PEG-SAHA, L-DSPE-PEG-K-182 and L-OL-PEG-SAHA had tumor suppressive effects on HeLa cells, indicating that K-182 or SAHA on the PEG-terminal of PEG-lipid via a carbamide bond was cleavable in the cells. Among the liposomal HDACI-lipid conjugates, L-OL-PEG-SAHA showed the highest antitumor effect on both HeLa and Colon 26 cells. DSPE-PEG-SAHA was anchored in liposomes via two alkyl chains, which could be easily retained liposome compared to OL-PEG-SAHA, which was anchored via one alkyl chain. Previously, we synthesized K-182-lipid conjugate, which bound to lipid via a carbamide or disulfide linker, into cationic nanoparticles and confirmed that the conjugates were activated by cleavage between K-182 and lipid. 15) Therefore, OL-PEG-SAHA might be efficiently released from L-OL-PEG-SAHA in the cells, and converted to SAHA by the cleavage of carbamide bond. However, it was not clear why L-OL-PEG-SAHA could induce higher cytotoxicity than free SAHA, but OL-PEG-SAHA might be stabilized hydroxamic acid by conjugation with PEG-lipid. We confirmed that oleyl-PEG 2000 did not show cytotoxicity at the concentra- tions used in this study (data not shown). Liposomes take advantage of the EPR effect for increasing their tumor accumulation when they are intravenously injected. 14) Liposomal HDACI-lipid conjugates might improve the pharmacokinetic and pharmacodistribution of the encapsulated drug. Liposomal LAQ824, hydrophilic hydroxamic acid HDAC inhibitor, was shown to be both long-circulating and highly stable in vivo. 14) In further study, we need to evaluate whether liposomal HDACI-lipid conjugation has antitumor effects by intravenous injection. Liposomal HDACIlipid conjugates might have potential as an effective vector in cancer therapy.
In this study, we synthesized HDACI-lipid conjugates and applied liposomal formulations. Liposomal HDACI-lipid conjugates could induce antitumor activity via acetylation of histone H3 and activation of caspase 3/7 in HeLa and Colon 26 tumor cells. These findings indicate that liposomal HDACI-lipid conjugates have potential as an effective vector in cancer therapy.
